MDMA-assisted therapy for PTSD: what does the evidence show?

What is being studied?

MDMA is a psychoactive substance that affects brain signalling. A defined research preparation given with structured psychological support is a different intervention from a pill or powder sold as ecstasy or molly, whose contents can be uncertain. The studies described here do not establish the safety or benefit of unsupervised use.

To understand how this trauma-related research differs from everyday stress, explore stress and mood.1

What did a PTSD trial find?

In a 2023 phase 3 trial, 104 adults with moderate to severe post-traumatic stress disorder (PTSD) were assigned MDMA with therapy or placebo with the same therapy programme. The MDMA group improved more on the main clinician-rated PTSD symptom measure. At the end of the study, 71.2% in the MDMA group and 47.6% in the placebo group no longer met PTSD diagnostic criteria among those assessed. This is not the same as being cured, and the results do not predict an individual outcome. The research was funded by the Multidisciplinary Association for Psychedelic Studies (MAPS), with foundation support.1

Why the comparison is difficult

Participants received preparation, supervised sessions and follow-up therapy. Noticeable drug effects can make it difficult to keep participants and therapists unaware of assignment, potentially influencing expectations and reported outcomes. FDA advisory discussion in 2024 addressed functional unblinding and missing data. The trial compared packages of care, not MDMA alone against no treatment, and its selected population and follow-up cannot resolve every question about durability or rare harms. Read how treatment comparisons work.12

Risks and the clinical setting

The trial reported adverse events in both groups; severe events occurred in five participants receiving MDMA-assisted therapy and two receiving placebo with therapy. Effects can include increases in blood pressure and heart rate as well as distress or other reactions, and eligibility screening and monitoring were part of the research. A trial cannot establish the identity or safety of an unregulated product. PTSD has established treatment options; discuss symptoms and treatment questions with a qualified clinician.1

Can MDMA cause overheating or low blood sodium?

Yes. MDMA can contribute to overheating, and drinking excessive water can also be dangerous. Low blood sodium, called hyponatraemia, can occur when the balance between water and sodium is disturbed; severe cases can cause confusion, seizures or collapse. These symptoms can have several causes and need urgent assessment.

A 2024 analysis combined data from four controlled studies involving 96 healthy volunteers given MDMA under supervision. Blood sodium fell below the study’s laboratory threshold in 30 participants during the measured period. This was a blood-test finding, not 30 cases of severe illness; the selected volunteers and controlled conditions do not give the risk in a club, a PTSD trial or any individual. The researchers investigated fluid intake and hormone changes, but their analysis does not establish a safe drinking amount outside clinical monitoring. The work was supported by Swiss research foundations.

If someone is very hot, confused, has a seizure, collapses or is difficult to wake, call emergency services immediately and tell responders what may have been taken. Do not delay care or try to fix the problem by forcing water or salt. See electrolytes and overhydration for the separate exercise context.56

What did the US FDA decide in 2024?

In its August 2024 complete response letter for Lykos Therapeutics’ midomafetamine application for PTSD, the FDA said it could not approve the application in its submitted form. The agency cited concerns about incomplete collection and reporting of safety events, uncertainty about whether benefits last beyond the main trial assessments, and possible selection and expectation biases. It described a new randomized trial with longer blinded follow-up as the most efficient way to address the clinical issues. This is the agency’s assessment of that application and its evidence at that time, not proof that the approach cannot work. An application can later be changed or resubmitted; check current FDA records for any subsequent decision.4

Access is specific to place and pathway

Australia’s Therapeutic Goods Administration describes an Authorised Prescriber pathway under which eligible psychiatrists may access unapproved MDMA-containing products for PTSD-assisted psychotherapy, subject to required approvals and local rules. This is a controlled access pathway, not general product approval or a rule for other countries. The US FDA convened an advisory committee in 2024 to discuss an MDMA application; an advisory meeting is not itself an approval decision. Check current regulator records for the exact product and country. Compare psilocybin evidence and status.32